Pharmaceuticals, Biotechnology and Life Sciences
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in…
SAN DIEGO–(BUSINESS WIRE)–$ARCT #BioCEO–Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused…
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in…
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in…
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in…
LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical…
The Phase 1b, randomized, double-blinded, dose escalation, single-center, repeat dose study design assessed the safety and pharmacodynamics with dapansutrile in…
DUBLIN–(BUSINESS WIRE)–The “BI 764524 – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering. BI…
OXNARD, Calif.–(BUSINESS WIRE)–$CURR #CBD—CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of…
OXNARD, Calif.–(BUSINESS WIRE)–$CURR #CBD—CURE Pharmaceutical Holdings (“CURE” or the “Company”) (OTC: CURR), a holding company focused on the innovation of…